Critical Analysis: Organon & Co. (NYSE:OGN) vs. Ryman Healthcare (OTCMKTS:RYHTY)

Ryman Healthcare (OTCMKTS:RYHTY) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Institutional & Insider Ownership

77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Ryman Healthcare has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Ryman Healthcare and Organon & Co., as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ryman Healthcare	0	0	0	0	0.00
Organon & Co.	2	5	0	0	1.71

Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 15.34%. Given Organon & Co.’s stronger consensus rating and higher possible upside, analysts plainly believe Organon & Co. is more favorable than Ryman Healthcare.

Profitability

This table compares Ryman Healthcare and Organon & Co.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ryman Healthcare	N/A	N/A	N/A
Organon & Co.	3.99%	99.95%	6.22%

Earnings and Valuation

This table compares Ryman Healthcare and Organon & Co.”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ryman Healthcare	$502.59 million	2.47	-$100.65 million	N/A	N/A
Organon & Co.	$6.22 billion	0.57	$187.00 million	$0.93	14.48

Organon & Co. has higher revenue and earnings than Ryman Healthcare.

Summary

Organon & Co. beats Ryman Healthcare on 10 of the 11 factors compared between the two stocks.

About Ryman Healthcare

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. The company's villages provide a range of retirement living and care options, such as independent townhouses and apartments, and serviced apartments, as well as a care center, which offers rest homes, hospitals, dementia-level care, and respite and day care services. Its villages also provide all-weather bowling green, indoor heated swimming pool and spa, gym, internal atrium, beauty and hair salons, library, dining area, bar, lounges, croquet laws, shops, and movie theatre facilities. The company owns and operates retirement village units and care units. The company was founded in 1984 and is based in Christchurch, New Zealand.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.